US FDA's Marks: Gene Therapy Success Could Hinge On Regulatory Convergence
Executive Summary
Biologics center's director encourages sponsors to invite other regulators to early FDA meetings in effort to scale up markets.
You may also be interested in...
Gene Therapy Manufacturing Hitch Solved, Bluebird Aims For European Debut In 2020
The EMA has declared itself satisfied with ‘refined manufacturing specifications’ for the beta thalassemia treatment
CBER Implements Pre-Clinical Meeting Program For Biologics, Gene Therapy Sponsors
INTERACT program will allow sponsors to ask FDA questions about manufacturing and other technical issues to help streamline development.
US FDA Could Use More Foreign Investigators If It Could Find Them, Woodcock Says
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: